Common (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitis
Uncommon (% to 1%): Cough, dyspnea, snoring, dysphonia
Rare (less than %): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions
Frequency not reported: Sleep apnea
Postmarketing reports: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome [ Ref ]
Any communications or information you transmit to this website by electronic mail or otherwise to Chattem shall be treated as non-confidential and non-proprietary. Although we welcome your comments and feedback with respect to this website or any of our products, we are not seeking and do not review any unsolicited ideas, suggestions or materials related to the development, design, manufacture or marketing of our products or the conduct of our business. This policy is intended to avoid confusion about the ownership of new ideas and concepts and to help protect you. By sending us any proposed ideas or other such information, you agree to transfer to Chattem all of your rights and interests in such proposed intellectual property, ideas and information. You further agree that any ideas, concepts or know-how that you or individuals acting on your behalf provide to Chattem can be used, reproduced, transmitted, disclosed or published by Chattem or its affiliates without restriction or compensation.